Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for monitoring worsening of hepatitis

A technology for hepatitis and severe disease, which is applied in the monitoring field of severe hepatitis and can solve unknown problems

Inactive Publication Date: 2007-10-10
PERSEUS PROTEOMICS INC +1
View PDF12 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, how GPC3 changes before the onset of liver cancer is completely unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for monitoring worsening of hepatitis
  • Drug for monitoring worsening of hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106] The acquisition of embodiment 1 natural type GPC3

[0107] HuH6 cells were cultured in large quantities using a dish with a diameter of 150 mm, and the culture supernatant was collected and purified. The culture supernatant was filled with DEAE Sepharose Fast Flow (Amersham CAT#17-0709-01), washed, and eluted with a buffer containing 500 mM NaCl. Next, after concentration with Centriprep-10 (Millipore CAT#4304), purification was carried out by gel filtration with Superdex 200HR 10 / 30 (Amersham CAT#17-1088-01) to obtain crude and purified GPC3.

[0108] In order to obtain high-purity GPC3, use a monoclonal antibody made of crude and purified GPC3 as an antigen to prepare an affinity column, fill it with HuH-6 crude and purified GPC3, and then wash it with pH 3.5, 0.1M glycine hydrochloric acid After that, in 4M MgCl 2 ·6H 2 O, and then dialyzed against 50 mM Tris-HCl (pH 7.5), 150 mM NaCl.

Embodiment 2

[0109] The acquisition of embodiment 2 recombinant GPC3

[0110]Use the plasmid DNA containing the full-length human GPC3 cDNA to construct the flag-added soluble GPC3, that is, construct the plasmid DNA expressing the recombinant GPC3 cDNA. A downstream primer (5'-ATAGAA TTC CAC CAT GGC CGG GAC CGT GCG C-3' (SEQ ID NO: 1)) designed to remove the hydrophobic region (564-580 amino acids) on the C-terminal side and an EcoRI recognition sequence, The upstream primer of the Kozak sequence (5'-ATA GGA TCC CTTCAG CGG GGA ATG AAC GTT C-3' (SEQ ID NO: 2)) was used for PCR. The resulting PCR fragment (1711 bp) was cloned in pCXND2-Flag. The prepared expression plasmid DNA was introduced into CHO cell DXB11 strain, and the CHO strain with high expression of soluble GPC3 was obtained by selection with 500 μg / mL Geneticin.

[0111] Use 1700cm 2 The spinner bottle of the flag-added soluble GPC3 high-expression CHO strain was carried out in large quantities, and the culture supernatant w...

Embodiment 3

[0112] Embodiment 3 Production of anti-GPC3 monoclonal antibody

[0113] Five Balb / C mice (CRL) were immunized with recombinant GPC3 or native GPC3. In the case of recombinant GPC3, the immunization protein was prepared to be 100 μg / mouse at the time of primary immunization; in the case of native GPC3, the immunization protein was adjusted to be 10 μg / mouse. The emulsified drug was subcutaneously administered using FCA (Freund's complete adjuvant (H37Ra), Difco (3113-60), Becton Dickison (cat#231131)). As a booster immunization, after 2 weeks, recombinant GPC3 was adjusted to 50 μg / mouse, and natural GPC3 was adjusted to 5 μg / mouse. The drug prepared above was emulsified with FIA (Freund's incomplete adjuvant, Difco (0639-60), Becton Dickison (cat#263910)), and the emulsified drug was subcutaneously administered. Thereafter, a total of 5 booster immunizations were performed at intervals of one week. For the final immunization, the same amount as the booster immunization was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method of monitoring worsening of hepatitis characterized by comprising assaying GPC3 with the use of an antibody which recognizes the GPC 3N end. According to this method, worsening of hepatitis, namely, progress of hepatitis or cirrhosis toward liver cancer can be presumed.

Description

technical field [0001] The present invention relates to a monitoring method for severe hepatitis and the monitoring drug. Background technique [0002] It is known that primary hepatocellular carcinoma (hereafter referred to as liver cancer) develops in most patients infected with hepatitis B and C viruses after developing from chronic hepatitis to liver cirrhosis. Among virus-infected patients, especially hepatitis C virus-infected patients, the conversion rate to liver cancer is high, and the incidence has also increased in recent years. Liver resection, percutaneous local therapy (radiofrequency ablation, ethanol infusion therapy, etc.), transarterial embolization (TAE), continuous arterial chemotherapy, radiation therapy, etc. are performed as treatment methods for liver cancer, but complete cure is often not achieved . Therefore, for the purpose of eliminating viruses and enhancing immunity in chronic hepatitis and liver cirrhosis in the transition stage of liver canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53G01N33/574C12N15/09G01N33/577
CPCG01N33/57438G01N33/576G01N2800/085
Inventor 中岛淳油谷浩幸岩成宏子大口正夫佐藤广一
Owner PERSEUS PROTEOMICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com